These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 34043007)

  • 21. Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis.
    Onur TS; Laitman A; Zhao H; Keyho R; Kim H; Wang J; Mair M; Wang H; Li L; Perez A; de Haro M; Wan YW; Allen G; Lu B; Al-Ramahi I; Liu Z; Botas J
    Elife; 2021 Apr; 10():. PubMed ID: 33871358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of Behavioral, Neuropathological, Brain Metabolic and Key Molecular Changes in zQ175 Knock-In Mouse Model of Huntington's Disease.
    Peng Q; Wu B; Jiang M; Jin J; Hou Z; Zheng J; Zhang J; Duan W
    PLoS One; 2016; 11(2):e0148839. PubMed ID: 26859386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic Update on Huntington's Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies.
    Dash D; Mestre TA
    Neurotherapeutics; 2020 Oct; 17(4):1645-1659. PubMed ID: 32705582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Translating Antisense Technology into a Treatment for Huntington's Disease.
    Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
    Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of huntingtin function slows synaptic vesicle endocytosis in striatal neurons from the htt
    McAdam RL; Morton A; Gordon SL; Alterman JF; Khvorova A; Cousin MA; Smillie KJ
    Neurobiol Dis; 2020 Feb; 134():104637. PubMed ID: 31614197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phenotype onset in Huntington's disease knock-in mice is correlated with the incomplete splicing of the mutant huntingtin gene.
    Franich NR; Hickey MA; Zhu C; Osborne GF; Ali N; Chu T; Bove NH; Lemesre V; Lerner RP; Zeitlin SO; Howland D; Neueder A; Landles C; Bates GP; Chesselet MF
    J Neurosci Res; 2019 Dec; 97(12):1590-1605. PubMed ID: 31282030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regional subcortical shape analysis in premanifest Huntington's disease.
    Tang X; Ross CA; Johnson H; Paulsen JS; Younes L; Albin RL; Ratnanather JT; Miller MI
    Hum Brain Mapp; 2019 Apr; 40(5):1419-1433. PubMed ID: 30376191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Msh2 acts in medium-spiny striatal neurons as an enhancer of CAG instability and mutant huntingtin phenotypes in Huntington's disease knock-in mice.
    Kovalenko M; Dragileva E; St Claire J; Gillis T; Guide JR; New J; Dong H; Kucherlapati R; Kucherlapati MH; Ehrlich ME; Lee JM; Wheeler VC
    PLoS One; 2012; 7(9):e44273. PubMed ID: 22970194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutant huntingtin reduction in astrocytes slows disease progression in the BACHD conditional Huntington's disease mouse model.
    Wood TE; Barry J; Yang Z; Cepeda C; Levine MS; Gray M
    Hum Mol Genet; 2019 Feb; 28(3):487-500. PubMed ID: 30312396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies.
    Wright GEB; Black HF; Collins JA; Gall-Duncan T; Caron NS; Pearson CE; Hayden MR
    Lancet Neurol; 2020 Nov; 19(11):930-939. PubMed ID: 33098802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nucleolar stress controls mutant Huntington toxicity and monitors Huntington's disease progression.
    Sönmez A; Mustafa R; Ryll ST; Tuorto F; Wacheul L; Ponti D; Litke C; Hering T; Kojer K; Koch J; Pitzer C; Kirsch J; Neueder A; Kreiner G; Lafontaine DLJ; Orth M; Liss B; Parlato R
    Cell Death Dis; 2021 Dec; 12(12):1139. PubMed ID: 34880223
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Salivary Huntingtin protein is uniquely associated with clinical features of Huntington's disease.
    Parkin GM; Corey-Bloom J; Snell C; Smith H; Laurenza A; Daldin M; Bresciani A; Thomas EA
    Sci Rep; 2023 Jan; 13(1):1034. PubMed ID: 36658243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Passive immunization against phosphorylated tau improves features of Huntington's disease pathology.
    Alpaugh M; Masnata M; de Rus Jacquet A; Lepinay E; Denis HL; Saint-Pierre M; Davies P; Planel E; Cicchetti F
    Mol Ther; 2022 Apr; 30(4):1500-1522. PubMed ID: 35051614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serine 421 regulates mutant huntingtin toxicity and clearance in mice.
    Kratter IH; Zahed H; Lau A; Tsvetkov AS; Daub AC; Weiberth KF; Gu X; Saudou F; Humbert S; Yang XW; Osmand A; Steffan JS; Masliah E; Finkbeiner S
    J Clin Invest; 2016 Sep; 126(9):3585-97. PubMed ID: 27525439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural Magnetic Resonance Imaging in Huntington's Disease.
    Wilson H; Dervenoulas G; Politis M
    Int Rev Neurobiol; 2018; 142():335-380. PubMed ID: 30409258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis.
    Tabrizi SJ; Scahill RI; Durr A; Roos RA; Leavitt BR; Jones R; Landwehrmeyer GB; Fox NC; Johnson H; Hicks SL; Kennard C; Craufurd D; Frost C; Langbehn DR; Reilmann R; Stout JC;
    Lancet Neurol; 2011 Jan; 10(1):31-42. PubMed ID: 21130037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice.
    Boudreau RL; McBride JL; Martins I; Shen S; Xing Y; Carter BJ; Davidson BL
    Mol Ther; 2009 Jun; 17(6):1053-63. PubMed ID: 19240687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peripheral huntingtin silencing does not ameliorate central signs of disease in the B6.HttQ111/+ mouse model of Huntington's disease.
    Coffey SR; Bragg RM; Minnig S; Ament SA; Cantle JP; Glickenhaus A; Shelnut D; Carrillo JM; Shuttleworth DD; Rodier JA; Noguchi K; Bennett CF; Price ND; Kordasiewicz HB; Carroll JB
    PLoS One; 2017; 12(4):e0175968. PubMed ID: 28453524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mapping the order and pattern of brain structural MRI changes using change-point analysis in premanifest Huntington's disease.
    Wu D; Faria AV; Younes L; Mori S; Brown T; Johnson H; Paulsen JS; Ross CA; Miller MI;
    Hum Brain Mapp; 2017 Oct; 38(10):5035-5050. PubMed ID: 28657159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic reversal of Huntington's disease by in vivo self-assembled siRNAs.
    Zhang L; Wu T; Shan Y; Li G; Ni X; Chen X; Hu X; Lin L; Li Y; Guan Y; Gao J; Chen D; Zhang Y; Pei Z; Chen X
    Brain; 2021 Dec; 144(11):3421-3435. PubMed ID: 34918046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.